Research programme: PARP inhibitors - AbbVie

Drug Profile

Research programme: PARP inhibitors - AbbVie

Alternative Names: A-620223; A-866111; ABT-472; ABT-880698; ABT-887563

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Benzimidazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Mar 2010 Preclinical development is ongoing in USA
  • 01 Sep 2008 Interim pharmacodynamics data from a preclinical trial in Cancer presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top